Page 48 - PAM_350

46 Panorama Actual del Medicamento

NUEVOS FÁRMACOS

Bibliografía

– – Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, Angiolillo DJ, Valgimigli M, Testa L, Gaita F, Sheiban I. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011; 150(3) : 325-31.

– – Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA. The effect of ticagrelor versus clo-pidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J. 2011; 162(1) : 160-5.

– – Cannon CP, Harrington RA, James S, Ardissino D, Bec-ker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and pa-tient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive stra-tegy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010; 375(9711) : 283-93.

– – Consejo General de Colegios Ofciales de Farmacéuti-cos. Bot PLUS WEB. https://botplusweb.portalfarma.com/ (visi-tada el 8 de noviembre de 2011).

– – European Medicines Agency. European Public As-sessment Report (EPAR). Gilenya. EMA/233042/2011;

EMEA/H/C/2202. http://www.ema.europa.eu/ (visitada el 8 de noviembre de 2011).

– – Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopido-grel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010; 121(10) : 1188-99.

– – Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ON-SET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery di-sease: the ONSET/OFFSET study. Circulation. 2009; 120(25) : 2577-85.

– – Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopido-grel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Pla-telet In-hibition and Patient Outcomes) trial. J Am Coll Car-diol. 2011; 57(6) : 672-84.

– – James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Ste-vens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syn-dromes intended for non-invasive manage-ment: substudy from prospective randomised PLATelet inhi-bition and patient Outcomes (PLATO) trial. BMJ. 2011; 342 : d3527.

– – James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute co-ronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation. 2010; 122(11) : 1056-67.

– – James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Ste-vens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010; 31(24) : 3006-16.

– – Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopi-dogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124(5) : 544-54.

– – National Institute for Health and Clinical Excellence. Ticagrelor for the treatment of acute coronary syndromes. NICE technology appraisal guidance 236 (October 2011). www.nice.org.uk/ta236

– – Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percuta-neous coronary intervention: A Platelet Inhibition and Pa-tient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010; 122(21) : 2131-41.

– – Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuels-son H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute co-ronary syndromes. N Engl J Med. 2009; 361(11) : 1045-57.